This content is machine translated Psoriasis in difficult localizations: Nail psoriasis IL-23 and IL-17 as a target – selected study findings Although nail psoriasis remains a challenge, considerable progress has been made in both diagnostic and therapeutic terms. This is reflected, for example, in current analyses of the GUIDE and ZODIPSO...…
View Post 5 min This content is machine translated Psoriasis: System therapies in everyday practice Current real-world data at a glance The better the efficacy of a systemic treatment, the higher the patient satisfaction, especially if the risk-benefit balance is favorable. This plausible correlation is impressively underpinned by current findings from...…
View Post 8 min This content is machine translated Psoriasis treatment with biologics What are the latest trends? Novel oral therapies are currently being researched – promising data from clinical trials is now available. In the field of approved, subcutaneously administered IL-23 and IL-17 antagonists, current real-world data...…
View Post 3 min This content is machine translated Risankizumab as a therapeutic option “Real life” interim balance: PASI 100 – realistic target Risankizumab has been approved in Switzerland since April 2019 for moderate to severe plaque psoriasis after unsuccessful therapy with conventional systemic treatment. The high and long-lasting efficacy with rapid response…
